Exploring the Science of Cognitive Function and Remyelination with Novel Therapies for Multiple Sclerosis


Course Information

Therapautic Area: Neurology
Format(s): Webcast
Credit(s): 2.00 AMA PRA Category 1 Credit(s)™
Activity Dates: December 21, 2016 - December 20, 2017


Program Overview

This educational program will highlight recent science and clinical data for the management of patients with multiple sclerosis. Expert faculty will discuss the mechanisms of remyelination in patients with multiple sclerosis. Updates on post-hoc clinical data for evaluating cognitive function will also be covered in the duration of this activity, and will be followed by panel discussions. Upon completion of this activity, physicians will gain a better understanding of the mechanisms of remylination along with updates in clinical data, ultimately improving patient outcomes.

Target Audience

Neurologists, and other healthcare professionals who care for patients with MS.

Educational Objectives

Upon completion of this activity, participants will be able to:

1. Describe the mechanisms of remyelination with multiple sclerosis therapeutics

2. Review post-hoc clinical data for evaluating cognitave function


dhib_jalbut_headshotSuhayl Dhib-Jalbut, MD
Department of Neurology
Rutgers Robert Wood Johnson Medical School
New Brunswick, NJ




Howard L. Weiner, MD

Robert L. Kroc Professor of Neurology Harvard Medical School
Director, Partners Multiple Sclerosis Center
Co-Director, Ann Romney Center for Neurologic Diseases
Brigham and Women’s Hospital
Boston, MA


Disclosure of Conflicts of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:


Faculty Relationship Identified With:
Suhayl Dhib-Jalbut, MD Consultant/Advisor: Biogen IDEC; Bristol-Myers Squibb Company; EMD Serono, Inc.; Genentech, Inc; Genzyme Corporation, a Sanofi company; Mallinckrodt Pharmaceuticals; Teva Pharmaceutical Industries Ltd.Grant/Research Support: Biogen IDEC; Teva Pharmaceutical Industries Ltd.
Howard L. Weiner, MD Consultant/Advisor: Teva Pharmaceutical Industries Ltd.; Tiziana Life SciencesGrant/Research Support: EMD Serono, Inc.; mIRagen Therapeutics; Sanofi-aventis U.S. LLC.; Teva Pharmaceutical Industries Ltd.; Vera Pharma Limited


Planners, Managers and Reviewers

Timothy Hayes, MD, PhD; Emma Gilmartin and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

AcademicCME designates this enduring material for a maximum of 2.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Financial Support

This activity has been supported by an independent educational grant from Biogen.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Biogen do not recommend the use of any agent outside of the labeled indications.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Physicians who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME Certificate.
  6. All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.


CME Inquiries/Special Needs

 For all CME inquiries or special needs, please contact admin@academiccme.com


      Provided by AcademicCME screen-shot-2016-12-01-at-11-31-00-am

This activity is supported by an educational grant from Biogen